RGC earnings date and last-quarter result: P/E -421.13. Updated 2026-07-23.
Regencell Bioscience Holdings (RGC) Research Hub
Regencell Bioscience Holdings (RGC) trades on NASDAQ, HK in the Healthcare (Drug Manufacturers - Specialty & Generic) sector. As of 2026-10-26, shares last closed at 6.76 USD (-11.86%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -421.13, market cap 2.99B. This hub links to the full technical, earnings and options research available for RGC.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - Specialty & Generic) |
|---|---|
| Exchange | NASDAQ, HK |
| Last close | 6.76 USD (-11.86%) |
| 52-week range | 4.67 USD – 19.9 USD |
| Trend regime | Range |
| 14-day RSI | 46.8 (Neutral) |
| Trailing P/E | -421.13 |
| Market cap | 2.99B |
| Dividend yield | 0.00% |
Available research for RGC
Covered Call on RGC: how it works, illustrative setup around the real 6.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RGC: how it works, illustrative setup around the real 6.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RGC: how it works, illustrative setup around the real 6.76 USD price, max profit/loss, breakeven and when to use it. Educational.
RGC technical analysis: range, last 6.76 USD, RSI 46.8, 52w range 4.67 USD–19.9 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RGC in?
Regencell Bioscience Holdings (RGC) is classified under Healthcare (Drug Manufacturers - Specialty & Generic), listed on NASDAQ, HK.
Is RGC in an uptrend or downtrend?
As of 2026-10-26, RGC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RGC's trailing P/E ratio?
RGC's trailing P/E is -421.13, with a market cap of 2.99B. See the earnings research page for full valuation detail.